Barcelona Court of Appeal confirms noninfringement of Novartis's rivastigmine patch patent

In its judgment of June 30 2017, the Barcelona Court of Appeal confirmed the Barcelona Commercial Court Number 4 first instance decision, which had dismissed the patent infringement action filed by Novartis against several generics for alleged infringement of European Patent 2’292’219 (EP’219).